share_log

Chardan Capital Initiates Coverage On Xilio Therapeutics With Buy Rating, Announces Price Target of $7

Benzinga Real-time News ·  Dec 21, 2022 06:22

Chardan Capital analyst Matthew Barcus initiates coverage on Xilio Therapeutics (NASDAQ:XLO) with a Buy rating and announces Price Target of $7.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment